News & Medias

The use of PET (Positron Emission Tomography) imaging is growing steadily worldwide. This technology is giving us new levels of precision and accuracy in oncology, cardiology and neurology. But starting a new radiopharmacy project can appear complex. In addition to handling the selection of hundreds of different pieces of equipment, materials and a highly-technical construction, there are numerous compliance and authorization procedures to follow. In this webinar, IBA’s experts will guide you through all the important steps to set up your GMP radiopharmacy. From the right questions to define your project and select your equipment to the support for quality assurance documentation/procedures, you will have a good overview to envision your future project.

The clinical value of myocardial flow quantification is supported by numerous observational and clinical studies in various populations. Its use is no longer restricted to a few academic centers as the technology advances and guidelines evolves. In this webinar two leading figures in the field discussed the clinical value and practical aspects of PET quantification in cardiovascular imaging and why and how to implement this modality in your institution. The practical aspects and clinical value of myocardial blood flow quantification in PET in patients with cardiovascular disease. By Piotr Slomka, PhD, FACC, FASNC, Director of Innovation in Imaging and Professor of medicine and cardiology, Division of Artificial Intelligence in Medicine at Cedars-Sinai. One of the most important advances in nuclear cardiology is the opportunity to quantify myocardial blood flow (MBF) and myocardial flow reserve (MFR) routinely as part of myocardial perfusion imaging (MPI) with PET. Dr Slomka will review practical aspects of the MBF measurements with PET and discuss its clinical value in the management of cardiac patients. How to implement a cardiac PET myocardial perfusion imaging program ? ( Due to the institution policy, the recording could not be shared). By Sharmila Dorbala, MD, MPH, FASNC, Director of Nuclear Cardiology at Brigham and Women’s Hospital and Associate Professor of Radiology at Harvard Medical School. Dr. Dorbala will give an overview of the advantages of PET at identifying coronary artery disease (CAD), related workflow and current guidelines: She will also share her experience on how to implement a PET cardiac program.

As our healthcare systems is constantly looking for more value medicine, the use of cardiac PET is rapidly expanding and becoming one of the pillar for cardiac imaging. Cardiac PET has been widely adopted because it provides : high diagnostic accuracy and it is safe, efficient and patient-centered. IBA invites you to attend a free webinar presented by 2 leading figures of Nuclear Medicine: Dr. Terrence Ruddy and Dr Parthiban Arumugam. What will you learn from the webinar ? Cardiac PET Myocardial Perfusion Imaging in 2020 Dr Ruddy will start with the basic of PET Cardiac imaging versus other modalities and share the recent advances in the field including the last results of the ISCHEMIA trial and coming CMS AUC (Appropriate User criteria) and its potential impact in the field. Dr. Terrence Ruddy, FRCPC,FACC is the Director of Nuclear Cardiology at University of Ottawa Heart Institute and a Professor of Medicine and Radiology at the University of Ottawa. How to implement a Cardiac PET Program in your site? Dr Arumugam will share his expertise on how to plan and implement a PET Cardiac Imaging Program covering resources (cost of equipment, tracers and staffing requirements) and supporting guidelines from national and international societies and also additional information that perfusion PET can offer over and above SPECT for a more precise diagnosis. Dr Parthiban Arumugam is a Consultant Nuclear Medicine Physician at Manchester University NHS Foundation Trust in the United Kingdom Society.

In this webinar, the speakers will highlight the synergy between highly sensitive imaging, the definition of an intermediate stage between non-disseminated tumor and widespread metastatic disease (oligometastatic state) and high-precision radiation therapy (Stereotactic Body Radiation Therapy - SBRT) focused to treat the oligometastatic lesions. What will you learn from the webinar ? • Impact of PSMA PET on management of patients with oligo metastatic prostate cancer By Dr. Jeremie Calais, Director of the Clinical Research Program of the Nuclear Medicine and Theranostics Division at UCLA. Dr Calais will cover the concept of oligometastatic disease in prostate cancer patients and the impact of PSMA PET imaging on the therapy management of those patients. • The Role of SBRT in the treatment of oligometastatic prostate cancer: Why & how SBRT for these patients By PD Dr. med. Stefan Körber, First Senior Medical Doctor at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany Dr. Körber will describe how the oligometastatic status of prostate cancer patients is defined on the basis of PSMA PET/CT and which strategies and modalities are applied for SBRT treatment of these patients • Quality assurance for SBRT treatments By Dr. Kai Schubert, Medical Physicist at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany. The extremely high precision of SBRT requires an extensive program of Quality Assurance, both for the treatment machines as for the patient-specific treatment plans. Dr. Schubert will explain current strategies and future developments in this field.